AI has accelerated drug discovery, but it has also shortened the window of competitive advantage. This article explores why patent strategy must evolve beyond protecting individual molecules to safeguarding the platforms, data, and infrastructure that create long-term business value.

Owning a patented molecule does not necessarily mean owning the innovation behind it. As AI transforms drug discovery, companies must understand how data, platforms, collaborations, and IP agreements shape long-term ownership, commercialization, and competitive advantage.

Explore Hylton-Rodic Law’s Q2 2026 highlights, including our new Adams Morgan office, AI patent strategy discussions, industry events, educational programming, and continued growth serving innovators in life sciences and technology.

AI is accelerating drug discovery and compressing the timeline for critical intellectual property decisions. This article explores how biotech and pharmaceutical companies can build stronger patent strategies, documentation practices, and decision frameworks to protect innovation and long-term enterprise value.

At Hylton-Rodic Law, we believe sustainable legal excellence starts with well-being. That’s why we created Sunshine Fridays, our summer policy where the team logs off at 1:00 PM ET each Friday. It’s part of our broader micro-wellness approach: small, consistent habits that support mental health, fuel focus, and foster a healthier way to practice law.
From quarterly mental health days to birthday PTO and a firmwide holiday week off, our wellness culture isn’t just a perk; it’s our strategy for meaningful, human-centered legal work.

Understanding intellectual property is essential for innovators and early-stage businesses. At Hylton-Rodic Law, we’re often asked these key questions, here are our quick answers to help you get started.